📢 Our practical guide to EBRT for HCC is out in PRO

Less of a lit review, more of a how-to for #radonc: pt selection, techniques, treatment delivery, special scenarios

Many thanks to all coauthors!
@ldawsonmd @AndrewMMoon @hmaxi_MD @MichaelYanMD

🔗 tinyurl.com/PROHCC

Join me at ACG’s 2026 Obesity and Metabolic Disorders School & Southern Regional Postgraduate Course, December 4–6 in Louisville, KY! I’m looking forward to sharing insights and connecting with the GI community.

Details & Registration: gi.org/2026southern/

Now is the best time in the history of cirrhosis care. And it will only get better.
This week we release the first set of guidelines on preventive care in cirrhosis in @AmJGastro @AmCollegeGastro

Open access: ovid.com/jnls/ajg/fullt…

Together with my coauthors (Jennifer C. Lai, MD/MBA), we lay out the evidence based strategies that prevent decompensation, hospitalization, and death for the more than 2 million Americans living with cirrhosis. We also walk through how to implement these concepts in practice

ACG Clinical Guideline: Diagnosis and Management of Adenomatous Colorectal Polyposis Syndromes

📕 bit.ly/acg-polyposis-…
🎙️ bit.ly/ajg-podcast-po…
📄 bit.ly/acg-polyposis-…

@GMankaney @burkegastrodoc @CarlKayMD @AndrewMMoon

🆕 ACG Guideline Highlights: Adenomatous Colorectal Polyposis Syndromes 🧬

▪️Germline testing triggers + MGPT panel
▪️FAP/AFAP/MAP surveillance intervals
▪️Gastric & duodenal (Spigelman) mgmt

Proud to have contributed concept & content

🔗bit.ly/acg-polyposis-…

More big funding news! Andrew Moon, MD, MPH, and Louise Henderson, PhD, were awarded $400,000 for their new study on the early detection of liver cancer in patients with advanced types of liver disease.

Congrats, Drs. Moon and Henderson! 🎉 news.unchealthcare.org/2026/06/unc-li…

Congratulations to past AASLD Foundation awardee @AndrewMMoon on receiving new NIH funding to advance the early detection of #livercancer in patients with #MASLD.

We're proud to support researchers whose work is improving the future of liver health!

🏥machine_perfusion (#MP) is increasingly being utilised for #DCD liver transplants.

In this #UNOS study from 2016 to 2025, we showed an accelerated, 7.8-fold increase in the use of DCD livers from donors ≥60 in the #MP_era, with a reduction of the median #waitlist #time from eptable early graft survival.

@_ILTS_
@ESOTtransplant
@Transpl_Int

frontierspartnerships.org/journals/trans…

So thrilled to see our collaborative publication with @tedradonc, @ma5RN and many others now online in @JCO_ASCO

These data from a large, multinational cohort provide further support for EBRT's role in the management of HCC.

ascopubs.org/doi/10.1200/JC…

This opportunity and collaborative effort would not have been possible without the support of the @AmCollegeGastro North American International GI Training Grant which provided support for my travel/training in Barcelona

Major international IPD effort by @ma5RN @AndrewMMoon and @tedradonc crafting a great team to assess the survival of almost 5000 HCC patients treated with EBRT and stratified by BCLC stage. Best information available to consider EBRT in clinical practice
pubmed.ncbi.nlm.nih.gov/42139645/

The Nurse expertise and knowledge as central players in the BCLC strategy for conventional care and research. pubmed.ncbi.nlm.nih.gov/41760133/ The strength of a team relies on all its members @gemmaiserte @nllarch @AndrewMMoon @ma5RN in @SeminLiverDis

Fantastic editorial board retreat for the @AmCollegeGastro @AmJGastro in beautiful Savannah.
Planning for next year, thinking hard about current challenges in academic publishing and, most importantly, discussing the benefits of coffee.

New ACG guidelines on hepatic encephalopathy March 2026 📌🧠

📸: journals.lww.com/ajg/fulltext/2…

⭐ Meet the 2026 Clinical Research Leadership Program #CRLP cohort!

These physician-scientists will receive training in clinical research management & convene w/ other #ACGInstitute programs at #LeadershipYOU in June 2026.

🎉Congrats!
#ACGfamily #FutureofGI @NeenaSAbrahamMD

Rural-Urban Disparities in Hepatocellular Carcinoma Deaths Are Driven by Hepatitis C-Related Hepatocellular Carcinoma
Moon, et al.

📕 doi.org/10.14309/ajg.0…

@AndrewMMoon @sasha_link @DavidMauroMD @MLongMD @JasmohanBajaj

Important updates on liver cancer epidemiology:

➡️60% diagnosed at early stage 👍
➡️Only 57% had cirrhosis diagnosed before HCC
➡️Y-90 most common first treatment
@DeptVetAffairs
sciencedirect.com/science/articl…

A BCLC systematic review/meta-analysis of OS of HCC patients with vasc invasion receiving treatment in @HEP_Journal Heterogeneity across cohorts prevents robust figures except with TARE that offers a a pooled 1-year OS of 34% (95%CI:2–48%) @hospitalclinic pubmed.ncbi.nlm.nih.gov/41397177/

Congrats to Gabe Lupu from @UNCGastro for an incredible talk on LIRADS discrepancies at @AASLDtweets #TLM25

We need to improve adoption of LIRADS for liver nodules in patients with cirrhosis and HBV throughout the US